News 18.03.2020 Schlieren (Zurich), Switzerland, March 18, 2020 – Kuros Biosciences (SIX: KURN) today announced that its subsidiary, Kuros Biosurgery AG, has been granted the US patent, US 10’589’001, entitled ‘Pharmaceutical formulation for use in spinal fusion’. This patent covers the use of parathyroid hormone (PTH) containing matrices for spinal fusion. The granting...
News 28.02.2020 Zurich, Switzerland – February 27, 2020 – Neurimmune AG, the discoverer of aducanumab and cinpanemab, announced today enrollment of the first patient in a Phase 1 clinical trial to evaluate NI006 in transthyretin amyloid cardiomyopathy (ATTR cardiomyopathy). NI006 is a human antibody directed against transthyretin amyloid (TTR amyloid) consisting of misfolded...
News 26.02.2020 Zurich-Schlieren, Switzerland, February 26, 2020. Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix, its blood-based test for prostate cancer diagnosis, has now been made commercially available in Europe. Proclarix combines proprietary biomarkers and a risk score that accurately identifies an individual patient’s risk for clinically significant prostate cancer. The...
News 20.02.2020 Zurich-Schlieren, Switzerland, February 20, 2020. Molecular Partners AG (SIX: MOLN), a clinicalstage biotech company that is developing a new class of drugs known as DARPin® therapies, today announced the nomination of three new board members, proposed for election at the 2020 Annual General Meeting on April 29, 2020. Nominees are as follows: • Sandip...
News 06.02.2020 Research & Development: Abicipar in Neovascular Wet Age-Related Macular Degeneration: Two-year results from CEDAR and SEQUOIA presented at AAO in October 2019 demonstrate that vision gains observed after one year with both, every 8-week and every 12-week dosing were maintained in second year FDA and EMA filings accepted and under...